Prevention of Human Papillomavirus (HPV) Infection in Paediatric Kidney and Liver Transplant Recipients and in Paediatric Patients With Advanced Chronic Kidney Disease

University Hospital Heidelberg140 enrolled

Overview

Due to their immunosuppressive therapy, solid-organ transplant (SOT) recipients bear a 10 to 100 times higher risk of human papillomavirus (HPV)-associated malignancies than healthy individuals. The objectives of this observational, non-interventional multi-national, multi-centre research project are to gain an insight into current HPV vaccination strategies and to investigate the immune response to different routinely administered HPV vaccines in European paediatric SOT candidates and immunocompromised transplant recipients, enabling patients at risk of vaccination failure to be identified.

Study Type

OBSERVATIONAL

Enrollment

140

Conditions

Paediatric Kidney or Liver Transplantation Chronic Kidney Disease

Eligibility

Sex: ALLMin age: 9 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Paediatric Kidney and/or Liver transplant recipients * Paediatric patients with CKD * Who receive HPV vaccination according to country-specific vaccine schedule Exclusion Criteria: * No HPV vaccination according to country-specific vaccine schedule * No written informed consent

Locations (1)

Outcomes

Primary Outcomes

Immune Response to HPV vaccine

HPV vaccine antibodies

Time frame: Change of immune response from baseline (prior to vaccination) to 4-12 weeks after vaccination and to 18+- 3 months after vaccination will be assessed.